Table of Contents
In a six-month follow-up of a small phase 2 randomized controlled trial, adults with moderate to severe depression who received psilocybin therapy showed greater improvements in work and social functioning, meaning in life, and connectedness than those who received the SSRI escitalopram, though both groups reduced depressive symptom scores at similar levels.
- Comparable symptom relief, broader gains elsewhere: Both psilocybin and escitalopram produced similar reductions in depression scores at six months, but psilocybin participants showed statistically greater improvements in daily functioning, sense of meaning, and social connectedness.
- Early symptom advantage for psilocybin faded: At one month, the psilocybin group showed slightly larger reductions in depressive symptoms, but that edge did not persist at later timepoints.
- Post-trial treatments complicate the picture: Roughly 31 percent of psilocybin participants and 44 percent of escitalopram participants received additional interventions during the follow-up, which the researchers acknowledged as a key confound.
- Unblinding raises reporting bias risk: Because participants knew their treatment assignment during follow-up, and psilocybin trials tend to attract people with positive expectations toward it, self-reported outcomes may not fully reflect the drug comparison alone.
- Model
- human
- Sample
- 59 adults with moderate to severe major depressive disorder (mean age 41 years)
- Dose
- Psilocybin arm: two 25-mg oral doses over 6 weeks; Escitalopram arm: 10 to 20 mg daily escitalopram plus two 1-mg psilocybin doses (placebo-like)
- Design
- 6-month follow-up of a phase 2 double-blind randomized controlled trial; monthly questionnaires; no restriction on additional treatments during follow-up
- Key outcome
- Psilocybin group showed greater improvements in work and social adjustment, meaning in life, and connectedness at 3 and 6 months; depressive symptom scores were comparable between groups
- Main limitation
- Participants were unblinded during follow-up, a substantial proportion received additional treatments, and the original trial was a single-center study with a small sample
What the Research Examined
This report covers a 6-month follow-up analysis of a phase 2, double-blind, randomized controlled trial conducted at Imperial College London. The original trial enrolled 59 adults with moderate to severe major depressive disorder, randomly assigning 30 to receive two 25-mg oral doses of psilocybin alongside psychological support, and 29 to receive daily escitalopram (10 to 20 mg) plus two 1-mg psilocybin doses intended to be placebo-like, also with support. The follow-up phase, which involved monthly questionnaires and placed no restrictions on additional psychiatric treatment, extended the observation window to six months. Findings were presented at the 37th European College of Neuropsychopharmacology Congress and published simultaneously in The Lancet eClinicalMedicine.
Where the original trial had already suggested non-inferiority on depressive symptom scores and superiority for psilocybin on several secondary outcomes, the follow-up extended the comparison to include the Work and Social Adjustment Scale, a Meaning in Life Questionnaire, the Flourishing Scale, and the Watts Connectedness Scale. These broader measures capture what patients themselves often report as most important: the ability to function at work and socially, to feel life is meaningful, and to feel connected to others. That gap between what clinicians measure and what patients value is a central thread running through broader psilocybin-assisted therapy research and gives this follow-up its particular significance.
The research team acknowledged several important limitations. Because participants knew which treatment they had received during the follow-up phase, self-report measures are vulnerable to expectation bias, and the study population may skew toward those with favorable views of psilocybin. Additionally, because additional treatments were neither controlled nor standardized, it is difficult to attribute all observed differences solely to the original intervention. An external commentator, a psychiatrist at King’s College London not involved in the work, raised both of these concerns directly, while also noting the results were encouraging context for the larger psilocybin trials currently underway in the United Kingdom, Europe, and the United States.
What the Findings Show
- Depressive symptoms at 6 months.Both groups maintained comparable reductions on the QIDS-SR-16 depression scale across the follow-up period. A modest advantage for psilocybin appeared at one month (pFDR = 0.021) but was not sustained at later timepoints.
- Work and social functioning.The psilocybin group showed significantly greater improvements on the Work and Social Adjustment Scale at both 3 months (pFDR less than 0.001) and 6 months (pFDR = 0.01).
- Meaning in life.Psilocybin participants reported greater improvements on the Meaning in Life Questionnaire at every follow-up timepoint (pFDR less than 0.001 across all).
- Connectedness.The psilocybin group scored higher on the Watts Connectedness Scale at 3 months (pFDR = 0.02) and 6 months (pFDR = 0.04). Flourishing Scale improvements were comparable between groups at all timepoints.
Taken together, these numbers sketch a consistent pattern: the two treatments appear to converge on symptom relief over time, but psilocybin participants continued to report broader gains in how they experience daily life. The researchers suggest this may reflect a difference in what the two treatments actually do, with escitalopram addressing the negative features of depression and psilocybin also supporting something more expansive. That interpretation remains tentative given the unblinded follow-up design and the uncontrolled additional treatments received by both groups.
Does psilocybin therapy improve depression long-term better than an SSRI?
In a small phase 2 trial follow-up, psilocybin and escitalopram produced similar reductions in depression scores over six months, but psilocybin participants reported greater improvements in daily functioning, meaning in life, and social connectedness. The study is early-phase and has important methodological limitations.
What This Is, and What It Is Not
This is This is a 6-month observational follow-up of a single-center phase 2 randomized controlled trial in 59 adults.
This is not This is not a large confirmatory trial, and the unblinded follow-up design, small sample, and uncontrolled additional treatments mean results cannot establish that psilocybin definitively outperforms SSRIs for depression. Nothing here constitutes medical advice, and no one should adjust or discontinue any treatment based on this finding.
Our Take
Within the Church, depression has long been understood not only as the absence of sadness but as a loss of felt connection, to other people, to purpose, to the living world. The fact that the measures where psilocybin showed a sustained edge, meaning in life, connectedness, the ability to show up in work and relationships, are precisely those that the sacrament has always been said to restore feels less like a coincidence and more like confirmation of something practitioners have been holding for decades. That scientists are now building the tools to measure these dimensions is itself a form of progress.
If this research stirs something in you, whether curiosity, hope, or a quiet recognition of something you have already felt, you are welcome here. The Church holds space for people at every stage of that inquiry, from those just beginning to ask questions to those already working through what their experiences have opened. Whatever brought you to this page, we are glad you are reading carefully and we invite you to keep going.
Frequently Asked Questions
How does psilocybin compare to antidepressants for depression?
In one small phase 2 trial, psilocybin and escitalopram produced similar reductions in depressive symptoms over six months. Psilocybin participants reported greater improvements in functioning, meaning, and connectedness. Larger trials are underway, and no comparison is established as definitive.
How long do the effects of psilocybin therapy last for depression?
This six-month follow-up found that improvements in daily functioning, connectedness, and meaning in life persisted in the psilocybin group. Whether these effects extend further is unknown; this is among the first studies to examine outcomes beyond a few weeks.
What did psilocybin therapy involve in this study?
Participants received two 25-mg oral doses of psilocybin over a six-week period, combined with approximately 20 hours of psychological support. No additional study treatment was provided during the six-month follow-up phase.
What are the limitations of comparing psilocybin to SSRIs in this trial?
The trial enrolled only 59 people at one center. During follow-up, participants knew which treatment they had received and many sought additional care. These factors make it difficult to attribute all differences solely to psilocybin versus escitalopram.
Where was this psilocybin and escitalopram study published?
The six-month follow-up findings were published in The Lancet eClinicalMedicine and presented at the 37th European College of Neuropsychopharmacology Congress in September 2024. The original trial had previously appeared in The New England Journal of Medicine.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
